Evaluation
*
HighAbove AverageAverageBelow AverageLow
Suzanne Walker, CRNP, MSN, AOCN, BC
Sukmani Padda, MD
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Discuss basic science behind the human immune response
Describe how the checkpoint inhibitors alter the body’s immune response to non-small cell lung cancer cells
Describe potential toxicities associated with checkpoint inhibitors, including etiology of these toxicities and management and/or prophylaxis
Explain how checkpoint inhibitors differ from other available treatment options for metastatic NSCLC, including kinase inhibitors and cytotoxic chemotherapy
Identify FDA approved checkpoint inhibitors and their indications, including relevant aspects of patient selection
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
This activity met my educational needs, expectations, and objectives
This activity was relevant to my practice
I feel confident treating patients in my practice based on this activity
This activity rates highly in comparison with other CE/CME activities in which I have participated in the last 12 months
The presentation was scientifically sound and free of commercial bias or influence
*
*
*
*
*